LGVNHealthcare · BiotechnologyThe 2 Wall Street analysts covering Longeveron, Inc. hold a median 12-month price target of $61 — +3567.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +3567.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | Maxim Group | Downgrade | Hold | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $8.00 |
| 15 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 June 2023 | EF Hutton | Assumes | Buy | $13 |
| 16 May 2023 | EF Hutton | Reiterates | Buy | — |
| 9 May 2023 | EF Hutton | Reiterates | Buy | — |
| 27 Mar 2023 | EF Hutton | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LGVN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 26% of US stocks
Cheaper than 82% of US stocks
Cheaper than 61% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 76% of US stocks
Higher than 4% of US stocks
Higher than 97% of US stocks
Higher than 7% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Longeveron, Inc. has a market value of $5.3M and an enterprise value of −$4.2M.
Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter shrank 9.2% year on year.
Net income over the same four quarters: −$23.5M, a −1977.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.7M.
Trailing P/E: 2.9×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Longeveron, Inc. employs 38 people — $31K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Longeveron retained Lucid Capital Markets, LLC as its financial advisor to explore potential strategic opportunities, including a potential business combination.
Why it matters — The engagement could inform the company’s strategic direction, and LGVN watchers may follow any developments from this review.
Longeveron reported updated ELPIS II Phase 2b results for laromestrocel in infants with HLHS. The trial did not meet its primary endpoint for change in RVEF at month 12, while additional analysis found a statistically significant difference in the prespecified MACE endpoint: 8 events in the standard-of-care arm versus 1 in the laromestrocel arm (P=0.043).
Why it matters — The findings add a secondary clinical outcome to the trial results, while the missed primary endpoint remains part of the update.
Longeveron Inc., a clinical-stage regenerative medicine biotechnology company developing cellular therapies for aging-related conditions, announced it will participate in three upcoming Longevity/Aging investment conferences. The announcement was made via GlobeNewsWire on September 30, 2026.
Why it matters — Participation in these specialized investment conferences could raise the company's visibility among investors focused on the longevity and aging sector, a core area of Longeveron's work.
Longeveron said it will explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
Why it matters — A LGVN watcher would care because the mid-stage trial failure raises questions about the company's pipeline and prompts a potential shift in strategy.
Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in 40 infants with hypoplastic left heart syndrome, indicating the trial did not meet its primary endpoint of improvement in right ventricular ejection fraction at month 12. The company is analyzing exploratory endpoints, plans to discuss a path forward with the FDA, and is exploring all options to maximize shareholder value.
Why it matters — The missed primary endpoint in a key Phase 2b trial represents a setback for laromestrocel's HLHS program and prompts the company to reevaluate its strategy and pursue cost-containment measures.
The 2 Wall Street analysts covering Longeveron, Inc. have a median 12-month price target of $61, with estimates ranging from $43 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Longeveron, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 35 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Longeveron, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +3567.7% from the last close, and Ticker Nerd's factor model ranks Longeveron, Inc. 35 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $80 over the next 12 months.
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Longeveron Announces Engagement of Lucid Capital Markets". Longeveron retained Lucid Capital Markets, LLC as its financial advisor to explore potential strategic opportunities, including a potential business combination.
Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.
CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com